The role of antimalarials in lupus nephritis: a review
© Lee et al; licensee BioMed Central Ltd. 2012
Published: 13 July 2012
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease affecting various organs, with lupus nephritis being one of the most important and common serious manifestations. Antimalarials (AM) are one of the many immunomodifying medications used in SLE, however less known is its role in lupus nephritis. Our study examined the history of AM use, theorized mechanisms of action, efficacy in SLE, in particular in lupus nephritis, safety in pregnancy, and overall safety profile.
We conducted a search of all relevant literature using Medline (OVID and EMBASE) and PubMed. We included randomized-controlled trials, observational cohort studies, and case-control studies. Case reports were only included for the adverse effect profile of AM.
•In patients with renal disease, caution with dosing and careful monitoring for adverse events should be taken.
AM are medications which confer many benefits to patients with SLE and lupus nephritis, with a good safety profile.
Senq-J. Lee: None; Earl D. Silverman: None; Joanne M. Bargman: None.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.